Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Identification and Functional Testing of ERCC2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and Ovarian Cancer

A. Rump, A. Benet-Pages, S. Schubert, JD. Kuhlmann, R. Janavičius, E. Macháčková, L. Foretová, Z. Kleibl, F. Lhota, P. Zemankova, E. Betcheva-Krajcir, L. Mackenroth, K. Hackmann, J. Lehmann, A. Nissen, N. DiDonato, R. Opitz, H. Thiele, K. Kast,...

. 2016 ; 12 (8) : e1006248. [pub] 20160809

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023790

Grantová podpora
NV15-28830A MZ0 CEP - Centrální evidence projektů

The increasing application of gene panels for familial cancer susceptibility disorders will probably lead to an increased proposal of susceptibility gene candidates. Using ERCC2 DNA repair gene as an example, we show that proof of a possible role in cancer susceptibility requires a detailed dissection and characterization of the underlying mutations for genes with diverse cellular functions (in this case mainly DNA repair and basic cellular transcription). In case of ERCC2, panel sequencing of 1345 index cases from 587 German, 405 Lithuanian and 353 Czech families with breast and ovarian cancer (BC/OC) predisposition revealed 25 mutations (3 frameshift, 2 splice-affecting, 20 missense), all absent or very rare in the ExAC database. While 16 mutations were unique, 9 mutations showed up repeatedly with population-specific appearance. Ten out of eleven mutations that were tested exemplarily in cell-based functional assays exert diminished excision repair efficiency and/or decreased transcriptional activation capability. In order to provide evidence for BC/OC predisposition, we performed familial segregation analyses and screened ethnically matching controls. However, unlike the recently published RECQL example, none of our recurrent ERCC2 mutations showed convincing co-segregation with BC/OC or significant overrepresentation in the BC/OC cohort. Interestingly, we detected that some deleterious founder mutations had an unexpectedly high frequency of > 1% in the corresponding populations, suggesting that either homozygous carriers are not clinically recognized or homozygosity for these mutations is embryonically lethal. In conclusion, we provide a useful resource on the mutational landscape of ERCC2 mutations in hereditary BC/OC patients and, as our key finding, we demonstrate the complexity of correct interpretation for the discovery of "bonafide" breast cancer susceptibility genes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023790
003      
CZ-PrNML
005      
20201023143909.0
007      
ta
008      
170720s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pgen.1006248 $2 doi
035    __
$a (PubMed)27504877
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rump, Andreas $u Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. German Cancer Consortium (DKTK), Dresden, Germany. German Cancer Research Center (DKFZ), Heidelberg, Germany.
245    10
$a Identification and Functional Testing of ERCC2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and Ovarian Cancer / $c A. Rump, A. Benet-Pages, S. Schubert, JD. Kuhlmann, R. Janavičius, E. Macháčková, L. Foretová, Z. Kleibl, F. Lhota, P. Zemankova, E. Betcheva-Krajcir, L. Mackenroth, K. Hackmann, J. Lehmann, A. Nissen, N. DiDonato, R. Opitz, H. Thiele, K. Kast, P. Wimberger, E. Holinski-Feder, S. Emmert, E. Schröck, B. Klink,
520    9_
$a The increasing application of gene panels for familial cancer susceptibility disorders will probably lead to an increased proposal of susceptibility gene candidates. Using ERCC2 DNA repair gene as an example, we show that proof of a possible role in cancer susceptibility requires a detailed dissection and characterization of the underlying mutations for genes with diverse cellular functions (in this case mainly DNA repair and basic cellular transcription). In case of ERCC2, panel sequencing of 1345 index cases from 587 German, 405 Lithuanian and 353 Czech families with breast and ovarian cancer (BC/OC) predisposition revealed 25 mutations (3 frameshift, 2 splice-affecting, 20 missense), all absent or very rare in the ExAC database. While 16 mutations were unique, 9 mutations showed up repeatedly with population-specific appearance. Ten out of eleven mutations that were tested exemplarily in cell-based functional assays exert diminished excision repair efficiency and/or decreased transcriptional activation capability. In order to provide evidence for BC/OC predisposition, we performed familial segregation analyses and screened ethnically matching controls. However, unlike the recently published RECQL example, none of our recurrent ERCC2 mutations showed convincing co-segregation with BC/OC or significant overrepresentation in the BC/OC cohort. Interestingly, we detected that some deleterious founder mutations had an unexpectedly high frequency of > 1% in the corresponding populations, suggesting that either homozygous carriers are not clinically recognized or homozygosity for these mutations is embryonically lethal. In conclusion, we provide a useful resource on the mutational landscape of ERCC2 mutations in hereditary BC/OC patients and, as our key finding, we demonstrate the complexity of correct interpretation for the discovery of "bonafide" breast cancer susceptibility genes.
650    _2
$a nádory prsu $x genetika $x patologie $7 D001943
650    _2
$a oprava DNA $x genetika $7 D004260
650    _2
$a ženské pohlaví $7 D005260
650    12
$a genetická predispozice k nemoci $7 D020022
650    _2
$a zárodečné mutace $7 D018095
650    _2
$a heterozygot $7 D006579
650    _2
$a lidé $7 D006801
650    _2
$a missense mutace $7 D020125
650    _2
$a nádory vaječníků $x genetika $x patologie $7 D010051
650    _2
$a xeroderma pigmentosum - protein skupiny D $x chemie $x genetika $7 D051759
655    _2
$a časopisecké články $7 D016428
700    1_
$a Benet-Pages, Anna $u MGZ-Medical Genetics Center, Munich, Germany.
700    1_
$a Schubert, Steffen $u Clinic for Dermatology Venerology and Allergology, Göttingen, Germany.
700    1_
$a Kuhlmann, Jan Dominik $u German Cancer Consortium (DKTK), Dresden, Germany. German Cancer Research Center (DKFZ), Heidelberg, Germany. National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany. Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany.
700    1_
$a Janavičius, Ramūnas $u Vilnius University Hospital Santariskiu Clinics, Hematology, Oncology and Transfusion Medicine Center, Vilnius, Lithuania. State Research Institute Innovative Medicine Center, Vilnius, Lithuania.
700    1_
$a Macháčková, Eva $u Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Foretová, Lenka $u Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Kleibl, Zdenek $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Lhota, Filip $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Zemankova, Petra $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Betcheva-Krajcir, Elitza $u Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. German Cancer Consortium (DKTK), Dresden, Germany. German Cancer Research Center (DKFZ), Heidelberg, Germany.
700    1_
$a Mackenroth, Luisa $u Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. German Cancer Consortium (DKTK), Dresden, Germany. German Cancer Research Center (DKFZ), Heidelberg, Germany.
700    1_
$a Hackmann, Karl $u Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. German Cancer Consortium (DKTK), Dresden, Germany. German Cancer Research Center (DKFZ), Heidelberg, Germany. National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany.
700    1_
$a Lehmann, Janin $u Clinic for Dermatology Venerology and Allergology, Göttingen, Germany.
700    1_
$a Nissen, Anke $u MGZ-Medical Genetics Center, Munich, Germany.
700    1_
$a DiDonato, Nataliya $u Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. German Cancer Consortium (DKTK), Dresden, Germany. German Cancer Research Center (DKFZ), Heidelberg, Germany.
700    1_
$a Opitz, Romy $u German Cancer Consortium (DKTK), Dresden, Germany. German Cancer Research Center (DKFZ), Heidelberg, Germany. National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany. Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany.
700    1_
$a Thiele, Holger $u Cologne Center for Genomics, Cologne, Germany.
700    1_
$a Kast, Karin $u German Cancer Consortium (DKTK), Dresden, Germany. German Cancer Research Center (DKFZ), Heidelberg, Germany. National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany. Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany.
700    1_
$a Wimberger, Pauline $u German Cancer Consortium (DKTK), Dresden, Germany. German Cancer Research Center (DKFZ), Heidelberg, Germany. National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany. Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany.
700    1_
$a Holinski-Feder, Elke $u MGZ-Medical Genetics Center, Munich, Germany.
700    1_
$a Emmert, Steffen $u Clinic for Dermatology Venerology and Allergology, Göttingen, Germany. Clinic of Dermatology, Rostock, Germany.
700    1_
$a Schröck, Evelin $u Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. German Cancer Consortium (DKTK), Dresden, Germany. German Cancer Research Center (DKFZ), Heidelberg, Germany. National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany.
700    1_
$a Klink, Barbara $u Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. German Cancer Consortium (DKTK), Dresden, Germany. German Cancer Research Center (DKFZ), Heidelberg, Germany. National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany.
773    0_
$w MED00008920 $t PLoS genetics $x 1553-7404 $g Roč. 12, č. 8 (2016), s. e1006248
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27504877 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20201023143907 $b ABA008
999    __
$a ok $b bmc $g 1239471 $s 984703
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 12 $c 8 $d e1006248 $e 20160809 $i 1553-7404 $m PLoS genetics $n PLoS Genet $x MED00008920
GRA    __
$a NV15-28830A $p MZ0
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Možnosti archivace